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Abstract: Matrix metalloproteinase9 (MMP9) is known to be highly expressed during metastatic
cancer where most known potential inhibitors failed in the clinical trials. This study aims to select
local plants in our state, as anti-breast cancer agent with hemopexin-like domain of MMP9 (PEX9)
as the selective protein target. In silico screening for PEX9 inhibitors was performed from our in
house-natural compound database to identify the plants. The selected plants were extracted using
methanol and then a step-by-step in vitro screening against MMP9 was performed from its crude
extract, partitions until fractions using FRET-based assay. The partitions were obtained by performing
liquid–liquid extraction on the methanol extract using n-hexane, ethylacetate, n-butanol, and water
representing nonpolar to polar solvents. The fractions were made from the selected partition,
which demonstrated the best inhibition percentage toward MMP9, using column chromatography.
Of the 200 compounds screened, 20 compounds that scored the binding affinity −11.2 to −8.1 kcal/mol
toward PEX9 were selected as top hits. The binding of these hits were thoroughly investigated and
linked to the plants which they were reported to be isolated from. Six of the eight crude extracts
demonstrated inhibition toward MMP9 with the IC50 24 to 823 µg/mL. The partitions (1 mg/mL) of
Ageratum conyzoides aerial parts and Ixora coccinea leaves showed inhibition 94% and 96%, whereas their
fractions showed IC50 43 and 116 µg/mL, respectively toward MMP9. Using MTT assay, the crude
extract of Ageratum exhibited IC50 22 and 229 µg/mL against 4T1 and T47D cell proliferations,
respectively with a high safety index concluding its potential anti-breast cancer from herbal.
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1. Introduction
Cancer cases were recently diagnosed in approximately 1,806,590 cases, which is the equivalent of
approximately 4950 new cases each day. In addition, there will be approximately 48,530 new cases
of ductal carcinoma in situ of the breast diagnosed in women [1]. It is also the second leading cause
of cancer-related deaths among women worldwide [2]. Breast cancer is classified into four major
molecular subtypes based on a few biomarkers such as hormone receptors (HRs), human epidermal
growth factor receptor 2 (HER2), and/or extra copies of the HER2 gene [3]. The subtypes i.e., luminal A
(HR+/HER2−), luminal B (HR+/HER2+), HER2+, and triple-negative (estrogen receptor, progesterone
and HER2-), have each different risk factors for incidence, disease progression, preferential organ
sites of metastases, and therapeutic response [4]. Although surgery and current chemotherapy have
shown positive treatment outcome for breast cancers, more effective drugs are still urgently needed
to improve the drug selectivity and to overcome drug-resistance [5,6]. The urgency is compounded
by the fact that only luminal A, luminal B, and HER2+ subtypes can be targeted by drugs such as
tamoxifen and trastuzumab [7]. Unfortunately, there is no drug found suitable for the triple-negative
type, although drugs such as carboplatin, paclitaxel, and doxorubicin are currently undergoing clinical
trials for triple-negative breast cancer in Canada [8].
Studies have shown that high expression of matrix metalloproteinase9 (MMP9) occurred in breast
cancer cells. MMP9 is a proteolytic enzyme belonging to MMP superfamily that lowers the value of the
extracellular matrix (ECM) causing angiogenesis and cancer cell migration [9,10]. The activity of the
enzyme is contributed by the zinc ion which interacts with the histidine triad in the catalytic site [11].
MMP9 was shown to be differentially expressed within different molecular subtypes of breast cancer.
Overexpression of MMP9 is a clear feature of triple-negative and HER2+ breast cancers [12] and studies
have suggested that MMP9 appears to be an important target for the triple-negative subtype of breast
cancer [13], as beside overexpression, it is also involved in extracellular-matrix remodeling, plays a
direct role in the expansion of tumor cells, and promotes tumor metastasis [10].
However, despite many efforts over many years to develop synthetic MMP inhibitors, all MMP
inhibitors have failed in the clinical trial stages because of the onset of significant dose-limiting
musculoskeletal toxicity or lack of efficacy [14]. These compounds have either a hydroxamate
functional group or related chelator chemistry that acts to perturb the critical coordinating zinc in the
catalytic domain, which results in the loss of enzymatic activity. Unfortunately, the catalytic site of
MMP9 is highly conserved in the whole of MMP’s family which results in non-selective inhibitions by
those compounds [15]. Thus, an alternative mechanism for targeting MMP9 in which the catalytic
zinc is not targeted has been proposed to overcome the selectivity issue [16]. Example of such an
alternative is targeting the hemopexin-like domain (PEX9) of MMP9 instead of the catalytic domain [17].
PEX9 contains non-conserved amino acid residues in its binding pocket [18] and is located next to the
catalytic site [19], thus targeting PEX9 might offer as a good strategy for the development of selective
inhibitors for the cancer treatment [20,21].
The use of natural product in cancer therapy has been attracting cancer survivors to
choose the material that they believe safer than the synthetic drugs [22]. This prompts so
many researches on natural product anticancer discovery to prove its scientific medicinal effect.
For example, Bacopaside (bac) I and II, which are triterpene saponins isolated from Bacopa monnieri,
significantly reduce the cell migration and its apoptosis, inducing combination of triple negative cancer
cell lines (MDA-MB-231) [23]. Another scientific proof on anticancer activity from natural product was
also shown by Elaeagnus angustifolia plant extract, which inhibits epithelial-mesenchymal transition
and induces apoptosis via HER2 inactivation and JNK pathway in HER2+ breast cancer cells [24].
Recently, anthocyanins, which are purified from Vitis coignetiae, enhances cisplatin sensitivity in MCF-7
human breast cancer cells through inhibition of Akt and NF-κB activation, strongly supports the use of
herbal remedies in cancer therapy [25].
In this present study, virtual screening against PEX9 was performed as the protein target to
shortlist compounds from natural product database potential in inhibiting MMP9 using in silico
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molecular docking. It is believed that the natural product compounds have unique structures (more
chiral carbon) [26] essential for further optimization. The shortlisted compounds would then be
correlated to their presence in the local plants. Eight plants were extracted using methanol and further
tested for their inhibition against MMP9 in vitro. From this result, four active extracts were partitioned
using four different solvents and then further in vitro screened for its activity against MMP9. The most
active partitions were then subjected to fractionation using column chromatography. The collected
fractions were then tested again against MMP9 and the active fraction was figured out for their
chromatography-mass profile using GC-MS. To support the potency as anti-breast cancer, four active
extracts were further evaluated for their inhibition against 4T1 cell, a triple-negative breast cancer cell
model. For comparison to the luminal A cancer cell type, the extract was also tested to T47D breast
cancer cell model. The flow chart of the studies is illustrated in Figure 1.
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2. Results 
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The control docking was carried out to assure that the parameters used in the docking 
simulation were correct. The results for the control docking showed the root mean square deviation 
(RMSD) between the docked and the crystal poses of the sulfate ion is 1.99 Å. Although the RMSD 
value is considered high for such a small compound, however, it is still within the prescribed 2 Å 
according to the literature [27]. The external validation was also carried out with a series of 
compounds previously tested for PEX9 inhibition experimentally to increase the confidence that the 
protocols used are appropriate. Figure 2a showed the overlapped docked poses of 17 ligands used in 
the external validation with the inset showed the superimposition of the docked and initial 
(crystallographic) poses of the sulfate ion. A blue shift in proMMP-9 tryptophan fluorescence was 
monitored to determine the binding affinity in dissociation constant (Kd) of all derivative 
compounds as previously described. The Kd was determined using the Prism software package 
(GraphPad V5) to fit the data to Equation: ΔF/ΔFMax in which ΔF is the nM shift for a given titration 
and ΔFMax is the maximal nM shift observed overall [28,29]. The activities of these compounds can be 
defined as active (Kd < 1.00 µM), marginally active (1.00 < Kd < 1.50 µM), or inactive (Kd > 1.50 µM) 
[30]. Based on this definition, it is noted that 11 of them are active, three compounds are marginally 
active, and another three are inactive. Nonetheless, based on the binding affinity, all the 17 
compounds are predicted to be active because their calculated binding affinity have negative values 
and are lower than that of the sulfate ion (−3.5 kcal/mol). Thus, when the calculated binding affinity 
was compared with the experimental Kd values, the results can be categorized into true positive (TP) 
Figure 1. The flo chart of the studies in bioguided fractionation of local plants to identify P9
inhibitors and breast cancer cytotoxic agents.
2. Results
2.1. Control Docking and External Validation
The control docking was carried out to assure that the parameters used in the docking simulation
were correct. The results for the control docking showed the root mean square deviation (RMSD)
between the docked and the crystal poses of the sulfate ion is 1.99 Å. Although the RMSD value is
considered high for such a small compound, however, it is still within the prescribed 2 Å according to
the literature [27]. The external validation was also carried out with a series of compounds previously
tested for PEX9 inhibition experimentally to increase the confidence that the protocols used are
appropriate. Figure 2a showed the overlapped docked poses of 17 ligands used in the external
validation with the inset showed the superimposition of the docked and initial (crystallographic) poses
of the sulfate ion. A blue shift in proMMP-9 tryptophan fluorescence was monitored to determine
the binding affinity in dissociation constant (Kd) of all derivative compounds as previously described.
The Kd was determined using the Prism software package (GraphPad V5) to fit the data to Equation:
∆F/∆FMax in which ∆F is the nM shift for a given titration and ∆FMax is the maximal nM shift
observed overall [28,29]. The activities of these compounds can be defined as active (Kd < 1.00 µM),
marginally active (1.00 < Kd < 1.50 µM), or inactive (Kd > 1.50 µM) [30]. Based on this definition,
it is noted that 11 of them are active, three compounds are marginally active, and another three
are inactive. Nonetheless, based on the binding affinity, all the 17 compounds are predicted to be
active because their calculated binding affinity have negative values and are lower than that of
the sulfate ion (−3.5 kcal/mol). Thus, when the calculated binding affinity was compared with the
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experimental Kd values, the results can be categorized into true positive (TP) for active compound
predicted active, and false positive (FP) for inactive compound predicted active as presented in Table S1
(Supplementary Materials). In this case, neither true negative (TN) for inactive compound predicted
inactive nor false negative (FN) for active compound predicted inactive, could be applied. The validity
of the control docking parameters was evaluated by the True Positive Rate (TPR). In machine learning,
the true positive rate, also referred to sensitivity or recall, is used to measure the percentage of actual
positives which are correctly identified [31]. The TPR was obtained by dividing the number of TP (11)
with the total compounds (17) and then multiplied by 100. The results showed that the TPR was equal
to 65%, indicate that the docking protocol is able to validate the activity of the published compounds.
Therefore, based on both control docking and external validations, the parameters of docking were
used for further virtual screening.
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Figure 2. Superimposition of (a) 17 published PEX9 inhibitor and (b) top twenty ligand scores docked
into PEX9 with deep pocket in the left side and shallow pocket in the right side. Inset is the control
docking of sulfate ion with green stick is initiate pose and red stick is re-docked pose. The external
ligands are colored in stick model with C = yellow; H = white; O = red; and N = blue. The protein
is presented in a surfaced form with magenta area = hydrogen bond donor; white = neutral and
green = hydrogen bond acceptor.
2.2. Virtual Screening
After validation, the docking protocol was then used to screen our in-house database that contained
200 natural compounds. The binding affinity was found to be contributed by the molecular interactions
such as steric interaction, hydrophobic interaction, and hydrogen bonding. Table 1 presents the top
20 ligands with the lowest binding affinity values related with their affinities toward PEX9. The top
20 ligands show the binding affinity in the range of −11.2 to −8.1 kcal/mol demonstrating their ability
to bind the binding pocket of PEX9 which is stronger than sulfate ion (control ligand). Figure 2b
illustrates the superimposition of the docked poses of the top 20 ligands at the binding pocket of PEX9.
The amino acid residues involved in the molecular interaction with the ligands are ALA13, GLU14,
GLY16, VAL58, PHE59, GLU60, PRO62, LYS65, ARG106, and GLN154.
2.3. Plants Extraction
Eight plants were selected for further extraction according to their availability in our surrounding
areas. These were Cordyline fruticosa (palm lily) leaves, Amaranthus spinosus (spiny amaranth) aerial
part, Turnera diffusa (damiana) leaves, Hibiscus rosa-sinensis (china rose) leaves, Ageratum conyzoides
(goat weed) aerial part, Ixora coccinea (jungle flame) leaves, Plumeria alba (white frangipani) leaves,
and Melaleuca leucadendron (cayuput) leaves. The yields of these extracts are presented in Table 2.
The condition of the extract was preserved so that no fungus or color changing occurred during the
storage as well as testing.
Molecules 2020, 25, 4691 5 of 17
Table 1. The binding affinity of the top 20 ligands from the herbal database with their corresponding
source plant.
PubChem ID Ligand Binding Affinity(kcal/mol) Plant
441207 digitoxin −11.2 Cordyline fruticosa
2724385 digoxin −10.4 Cordyline fruticosa
91540 gitoxin −10.1 Cordyline fruticosa
10328286 thonningianin A −9.1 Piper betle
6325284 amaranthin −8.7 Amaranthus spinosus
4483248 ophiopogonin C −8.6 Parkia javanica
92825 gypsogenin −8.6 Turnera diffusa
101277 pachyrrizin −8.5 Pachyrhizus erosus
5484010 sequoiaflavone −8.4 Elateriospermum tapos
11467 γ-terpineol −8.4 Melaleuca leucadendron
15411208 2,3-dihydrowithaferin A −8.4 Withania somnifera
72307 sesamin −8.3 Ageratum conyzoides
100257 Thalrugosin −8.3 Cyclea barbata
15484640 ixorapeptide I −8.3 Ixora coccinea
23265223 quercetin−3-O-(3′6”-O-di-p-coumaroyl)-glucoside −8.2 Hibiscus rosa-sinensis
131750919 Cryptochrome −8.2 Averrhoa carambola
92097 Taraxerol −8.2 Plumeria alba
99620 Homoaromoline −8.2 Arcangelisia flava
162807 (−)-glyceollin I −8.1 Glycine soja
490367 19-α-hydroxyasiatic acid −8.1 Cordyline fruticosa
Table 2. The extract yields from eight selected plants and their % inhibition against MMP9 in vitro at
1 mg/mL alongside with their IC50.
Crude Extract Yields (%) % Inhibition ± SEM IC50 ± SEM (µg/mL) R2
Cordyline fruticosa leaves 43 −6 ± 12 ND ND
Amaranthus spinosus aerial part 62 81 ± 4 783 ± 40 0.7501
Turnera diffusa leaves 65 55 ± 4 495 ± 20 0.9898
Ageratum conyzoides aerial part 65 75 ± 3 64 ± 14 0.8071
Ixora coccinea leaves 81 86 ± 1 82 ± 3 0.9879
Hibiscus rosa-sinensis leaves 72 55 ± 2 822 ± 20 0.9723
Plumeria alba leaves 77 85 ± 9 24 ± 8 0.8268
Melaleuca leucadendron leaves 41 −15 ± 14 ND ND
ND = not determined.
2.4. Bioguided Fractionation against MMP9
The eight crude extracts were then tested for their inhibitions toward MMP9 using the in vitro
Fluorescence Resonance Energy Transfer (FRET)-based assay. In the first screening, the concentration
used was 1000 µg/mL. This is considered as the highest concentration in which crude extract was still
soluble in the solvent used. Six of the eight crude extracts demonstrated more than 50% inhibition
toward MMP9. Only extracts from Cordyline and Melaleuca showed negative value for its % inhibition.
This could be due to the fluorescence background of the extract itself or possibly the extracts triggered
the MMP9 activity, thus negate the needs for further investigation.
The highest inhibition was performed by Ixora (86%), Plumeria (85%), Amaranthus (81%),
and Ageratum (75%). Both Hibiscus and Turnera only showed 55% inhibition. However, following the
IC50 determination (Table 2), the most potent extract is Plumeria (24 µg/mL) followed by Ageratum
(64 µg/mL), and Ixora (82 µg/mL). While, the other three extracts that showed IC50 > 100 µg/mL are
Turnera (495 µg/mL), Amaranthus (783 µg/mL), and Hibiscus (822 µg/mL). It can be seen that although
Amaranthus show high percentage of inhibition, its IC50 is considered as moderate. This might be due
to the weaker binding of the compounds present at the PEX9 site, thus higher concentration (up to
1 mg/mL) was required to reach for at least 50% inhibition.
According to the MMP9 inhibition performed by the extracts, top four extracts with the IC50 values
less than 500 µg/mL were partitioned using four different solvents and seeded for further in vitro assay
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against MMP9. The in vitro results of these partitions were presented in Figure 3 in which most of
Ageratum and Ixora partitions show higher inhibition than Plumeria and Turnera. Therefore, in the
next step, the best partitions of Ageratum (n-hexane) and Ixora (ethyl acetate) were subjected to the
fractionation using column chromatography.
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Figure 3. The histogram of inhibition percentage from 15 partitions from methanol extract of each plant
measured by FRET-based assay against MMP9 activity in vitro. N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycyl
hydroxamic acid (NNGH) was used as the positive control by showing 100% inhibition at 1 µM. The bars
described the standard error of triplicate assay.
From n-hexane partition of Ageratum, on the one hand, four fractions were collected. On the
other hand, ethyl acet te partition of Ixora was fraction te into three fractions. On fractio for
each partition with the highest yields (fraction 2 of Ageratum and fraction 1 of Ixora; Table S2) was
selected for the final evaluation of in vitro MMP9 inhibition as presented in Figure 4. From the result ,
it was observed that both Ageratum and Ixora fractio s performed high inhibitions against MMP9,
IC50 43 ± 60 µg/mL and 116 ± 18 µg/mL, respectively. Therefore, it could b shortly concluded that the
bioguided assay against MMP9 has been successfully p rformed on t herbal samples whic was
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and (b) Ixora leaves and (c) NNGH as the results of FRET-based assay toward MMP9. NNGH was
used as the positive control by showing IC50 47.8 nM. The bars showed the standard error of triplicate
assay as previously described.
2.5. In Vitro Cytotoxicity Assay
To support the in vitro enzymatic results, four top active extracts against MMP9 were further
evaluated for their capability to inhibit 4T1, a breast cancer cell model having triple-negative type
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from mouse. This cell has been known to express MMP9 during breast cancer. The results of in vitro
cytotoxicity assay are tabulated in Table 3. From the table, Ageratum extract is identified as the most
active sample to inhibit the proliferation of 4T1 cell with IC50 22 µg/mL. Interestingly, the IC50 of
Ageratum extract was lower than the positive control, doxorubicin (IC50 = 37 µg/mL) describing the
better potency of Ageratum extract than doxorubicin as antimetastatic agent. The other three extracts,
i.e., the leaves of Ixora, Turnera, and Plumeria demonstrated moderate activities against 4T1 cell
growth with IC50 270, 104, and 151 µg/mL. The morphologies of 4T1 cells before and after the treatment
with the four most active extracts are illustrated in Figure 5.
Table 3. The results of in vitro cytotoxicity assay of four extracts against 4T1 and T47D cell growth.
IC50 here describes the concentration of the extract that inhibits at least 50% cell proliferation, whereas
the safety index (SI) is the ratio between IC50 of cancer cells (4T1 and T47D) with the IC50 of Vero cells.
No Sample IC50 ± SEM (µg/mL) SI
4T1 (R2) T47D (R2) Vero (R2) 4T1 T47D
1 Turnera diffusa leaves 104 ± 5 (0.9192) 1295 ± 9 (0.9680) 613 ± 6 (0.9298) 5.90 0.47
2 Ageratum conyzoides aerial part 22 ± 14 (0.9388) 163 ± 3 (0.9387) 307 ± 5 (0.9708) 14.27 1.88
3 Ixora coccinea leaves 270 ± 3 (0.9887) 2200 ± 42 (0.8831) 653 ± 10 (0.9058) 2.42 0.29
4 Plumeria alba leaves 151 ± 4 (0.9566) 229 ± 4 (0.9741) 225 ± 4 (0.9741) 1.49 0.98
5 Doxorubicin 37 ± 6 (0.9483) 9 ± 4 (0.8740) 211 ± 7 (0.9549) 5.71 24.59Molecules 2020, 25, x FOR PEER REVIEW 8 of 18 
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Figure 5. The 4T1 cell morphologies after and before treating with four top active extracts as followed;
(a) untreated cell, (b) Ixora leaves, (c) Turnera leaves, (d) Ageratum aerial part, and (e) Plumeria leaves.
The arrow indicates the living cell for the white nodes whereas the death cell is black node surrounded
by white line.
As illustrated in Figure 5a, untreated 4T1 cells showed large cell shape with firm cell nucleus,
whereas the 4T1 cells treated with the extracts (Figure 5b–e) resulted in a decrease of living cell
populations compared to the untreated cells. The cells appeared round and fragmented indicating a
change in the cell morphology. The result indicated that Ageratum was cytotoxic to 4T1 breast cancer
cells and has the potential as an anti-proliferative agent. However, further investigation is needed to
confirm that these changes that caused the cell death are due to the process of either necrosis, apoptosis,
or the proliferation inhibition.
In the T47D cytotoxicity evaluation, the highest inhibition was also demonstrated by Ageratum
extract with its IC50 163 µg/mL, followed by Plumeria (IC50 229 µg/mL), meanwhile Turnera and
Ixora showed lower inhibition activities with their IC50, respectively 1295 µg/mL and 2200 µg/mL.
To determine the safety index, cytotoxicity assay on the non-tumorigenic cell line was also conducted.
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The results showed that the IC50 of Ageratum, Plumeria, Turnera, and Ixora against Vero cell were,
respectively, 307 µg/mL, 225 µg/mL, 613 µg/mL, and 653 µg/mL. The safety index is calculated by
dividing the IC50 of extract in the Vero cell by the IC50 of extract in individual cancer cell as presented
in Table 3. As shown, the safety index of Ageratum is the highest value among other extracts in both
4T1 (SI = 14.27) and T47D (SI = 1.88) indicating the least toxic of the extracts to the cells. The drug-dose
response curve of Ageratum extract against 4T1, T47D, and Vero cells was presented in Figure 6.Molecules 2020, 25, x FOR PEER REVIEW 9 of 18 
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2.6. TLC and GC-MS Profiles
According to the TLC profile, the fraction 2 of Ageratum showed three dark spots at the top site
of the TLC plate when it was detected under UV254 (see Figure 7a,b). There were two other spots
with a green color also detected under UV254 and visible light. Under UV365, all spots were detected
having fluorescence, therefore, it could be assumed that the compounds should have chromophore
and a long auxochrome aside with a rigid structure. On the other hand, the fraction 1 of Ixora contains
six spots under UV254 (see Figure 7c,d). Of these, one was a dark spot and the other five green spots,
which could be associated to the chromophore and a long auxochrome. In contrast, the dark spot
was undetectable under UV365, which could be due to the non-rigid structure. The green spots were
detected as a pink fluorescence under UV365, which could be associated with its rigid structure.
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The GC chromatogram of Ageratum fraction (fraction 2) and its mass spectra are presented in
Figures 8 and 9, respectively. The fraction 2 was separated into four peaks having Rt as followed:
Rt 8.825 min, 11.255 min, 12.175 min, and 14.460 min. These peaks were detected as compounds with
the mass/ion 522, 538, 543, and 539, respectively. On the other hand, the fraction of Ixora (fraction 1) was
separated into three peaks, detected at Rt 10.709 min, 12.380 min, and 14.153 min for their respective
mass/ion 548, 529, and 528 (see Figure S1).Molecules 2020, 25, x FOR PEER REVIEW 10 of 18 
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3. Discussion
Molecular docking has been applied successfully to discover potent compounds from natural
products for various diseases such as neuraminidase inhibitors [32], dengue protease inhibitors [33],
and cancers [34]. In the current study, in silico screening using molecular docking has been applied to
search for natural product compounds that have the potentials to be developed as a chemotherapeutic
agent for breast cancer through PEX9 inhibition.
In the assay system, the extract was added into the sample in order to prevent the binding of
the peptide substrate into the enzyme. Peptide substrate has a fluorophore that is connected by an
amide link. When the enzyme cleaves it, the fluorophore is released and fluorescence is detected by
the UV detector. The presence of the crude extract supposedly reduces the fluorescence reading as
the activity of the enzyme is inhibited. The positive control used in this study is NNGH, which is a
hydroxamate compound known to bind to MMP at the catalytic site. This catalytic site is composed
by zinc ion coordinated by histidine triad (401, 405, and 411) and essential residue of GLU402 [35].
The hydroxamate group will form a chelate with the zinc ion as well as GLU402 to attract water which
is closer to scissile amide bond of the inhibitor, thus preventing the proteolysis of the peptide substrate
by the enzyme.
The six of eight plants inferred from the in silico screening results showed significant inhibition
to MMP9. The fact that the protein model used in in silico screening is the hemopexin domain
of MMP9, therefore, the activities of the eight extracts are postulated to inhibit the PEX9 domain.
Based on the results of the in vitro MMP inhibition assay, extracts that showed IC50 ≤ 100 µg/mL were
further selected for the cytotoxicity assay to investigate the inhibition on the 4T1 cells proliferation.
According to National Cancer Institute (NCI, Bethesda, MD, USA), the level of crude extract’s inhibition
with IC50 not greater than 20 µg/mL is categorized as active [36]. As observed, the four extracts showed
the IC50 at the range being considered as active to moderately active. This corresponds to the results
of the in vitro study against MMP9, especially for Ageratum conyzoides where the extract, partitions,
and fraction demonstrate quite good activities in inhibiting MMP9. Furthermore, the extract also
actively inhibited the proliferation of 4T1 metastatic breast cancer cells. All Ageratum samples could
be suggested to prevent the peptide substrate binding in the catalytic site of MMP9 by interrupting
the homodimerization of PEX9 [17]. However, further investigation is still warranted to confirm the
activity of the extract on the cell migration assay. The selectivity of the extracts toward MMP9 and
MMP2 should be performed because both have homology in their catalytic domain but non-homology
in their PEX domain. The extract that inhibits MMP9 activity better than MMP2 could be associated to
having selective inhibition toward MMP9. If the extract activity is about same toward both enzyme,
it could be non-selective inhibition that leads to adverse side effect.
GC-analysis and the mass spectroscopic analysis of Ageratum fraction shows a few compounds
with m/z 522–543 which has not been reported elsewhere [37–41]. The absence of the hit compound
of Ageratum namely sesamin with m/z 354 in the MS result means that there are some different
compounds responsible for the MMP9 inhibition. As such, the MS results of Ixora fraction do not
exactly determine the presence of its hit (ixorapeptide I; MR 500.6 g/mol) [42] as predicted by in silico
screening. However, the m/z of the compounds range from 528–548 assuming the compounds could be
a modified ixorapeptide.
According to the cytotoxicity assay, the Ageratum extract tends to be more selective to a
triple-negative breast cancer cell than luminal A, because the IC50 of the respecting extract is lower
when it was treated with 4T1 cell than with T47D cells. This shows a stronger interaction of the extract
with the MMP9 protease enzyme than either with the estrogen receptor or progesterone receptor which
is commonly present in luminal A cancer type. In contrast, doxorubicin was more potent to T47D
(IC50 9 µg/mL) than to 4T1 (IC50 37 µg/mL). This could be the reason why the activity of Ageratum
extract is stronger in 4T1 than T47D. Furthermore, the SI of Ageratum extract against 4T1 (14.27) is
considerably high and even better than doxorubicin (SI 5.71), therefore the activity of the Ageratum
extract is associated to its selectivity rather than cytotoxicity which is good for anticancer drug.
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Previous study reported that Ixora flower aqueous extract demonstrated antiproliferative activity
with IC50 of 31.3 µg/mL toward human breast adenocarcinoma cells [43]. Another study reported
that Ixora flower ethanolic extract can reduce the proliferation of human prostate cancer cell line
(LNCAP) with IC50 233.9 µg/mL without causing toxicities [44]. Prabhu et al. (2018) supported the
previous finding by reporting the antiproliferative activity against Dalton’s lymphoma ascetic (DLA)
cells and Erlich Ascites Carcinoma (EAC) cell lines. The flowers were extracted using petroleum
ether and methanol extract, and the result showed that the methanol extract performed the best
activity with IC50 250 µg/ mL and 300 µg/mL against DLA and EAC, respectively [45]. A recent
study of Ixora antiproliferative activity was performed against three different human cancer cell lines,
i.e., uterine cervical (HeLa), lung (NCI H-460) and breast (MCF-7) cancer cell lines. The chloroform
extract of this flower exhibited IC50 as follows: 15 µg/ mL, 3.8 µg/ mL, and 230 µg/ mL toward HeLa,
NCI H-460, and MCF-7, respectively [46].
On the other hand, an ethylacetate extract of Ageratum leaves exhibited the cytotoxic activity
on adenocarcinomic human alveolar basal epithelial cells (A-549) and leukemia cancer cells (P-388)
with IC50 values of 0.68 and 0.0003 µg/mL, respectively [47]. To date, there have been not so many
cancer cytotoxic study on Ageratum, but more recent research reported that the leaf aqueous extract
was reported to inhibit the proliferation activity of leukemic (Jurkat) cells with IC50 408.15 µg/mL and
non-toxic activity toward a normal prostate cell lines (PNT2) [48].
Presently, the antiproliferative activity of Ixora and Ageratum contributes significantly to anticancer
drugs than the traditional herbal sources as shown in previous studies, especially for the investigation
of potential anticancer effect through molecular mechanism of MMP9 in the triple negative cancer
type. This sharpens our hypothesis to the conclusion that both Ixora and Ageratum have cancer
cell antiproliferative activity, which is due to the MMP9 inhibition, leading to more selective cancer
chemotherapy. Attention is paid more to Ageratum than Ixora, as its methanol extract showed
IC50 22 µg/mL with SI 14.27 against metastatic cancer line, which is closer to the expected drug-like
properties than the previously reported. To the best of our knowledge, the activity of methanol extract,
its partition (n-hexane, ethylacetate, n-butanol) and the n-hexane: ethylacetate fractions of both herbs
could be potential for novel triple negative anticancer agents from herbal sources, which is not only
effective to the cancer cells but also selective toward the normal cells.
4. Materials and Methods
4.1. Software and Hardware
PEX9, PDBID: 1ITV [49] was downloaded from the Protein Databank (PDB, www.rcsb.org),
and the structures of known PEX9 inhibitors (external validation data) that have arylamide
structure linked to the planar pyrimidine ring by flexible ethylene chain were taken from published
literatures [24,25]. We created an in-house natural compound database containing 200 compounds
(ligands). The information on natural compounds was collected from Indonesia’s Herbal Remedies
Database (http://herbaldb.farmasi.ui.ac.id), Nature Based Discovery (NADI) System [32] and Natural
Product Activity and Species Source Database (http://bidd2.nus.edu.sg) [50]. The 3D structures’
files of the natural compounds were then downloaded from PubChem (https://pubchem.ncbi.nlm.
nih.gov/compound). The in silico screening used molecular docking protocol in AutoDock Vina
(autodock.scripps.edu) and the output was visualized using Discovery Studio 3.5 (www.accelrys.com).
HP laptop with Core i3 processor on Windows 10 operating system with 4 GB RAM and 500 GB Hard
Disk was the hardware.
4.2. Chemicals
Methanol and other organic solvents, silica for column chromatography, and thin layer
chromatography (TLC) F254 plates with analytical grade were purchased from Merck, Darmstadt,
Germany. The MMP9 enzyme kit was obtained from BioVision comprised of lyophilized MMP9,
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FRET-based MMP9 substrate (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg), MMP9 assay buffer, and NNGH
inhibitor (N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycyl hydroxamic acid) as its positive control.
4T1 cells (American Type Culture Collection, Manassas, VA, USA), were cultured in RPMI-1640 medium
containing 10% (v/v) fetal bovine serum (FBS) and 1% penicillin–streptomycin (Life Technologies,
Carlsbad, CA, USA) at 37 ◦C in 5% CO2 humidified incubator. T47D cells and RNase were courtesy from
Parasitology Laboratory, Medical Faculty, Gadjah Mada University cultured in Dulbecco’s Modified
Eagle Media (DMEM). Doxorubicin (DOX) and 3-(4,5-dimethylthiazol-zyl)-2,5-diphenyl tetrazolium
bromide (MTT) were obtained from Sigma, St. Louis, MO, USA.
4.3. Control Docking and External Validation
The crystal structure of PEX9 with sulfate ion was downloaded from the Protein Data Bank (PDB)
with PDBID 1ITV. This ion was used as the native ligand and found located at blade 3 and blade 4 of
the pocket site. PEX9 was presented as homo-dimer in the crystal structure and in this study, only one
monomer was used in the modeling. The sulfate ion was separated from PEX9 using Discovery
Studio 3.5, saved as PDB file and then assigned with Gasteiger Charges using AutoDockTools1.5.6 [51].
PEX9 was prepared using the same program whereby polar hydrogens were retained and the molecule
was assigned with Kollman charges. The grid box was automatically defined by PyRx program
(exhaustiveness = 32; size 25, 25, 25 and center x = −42.05, y = −30.85, z = −7.26) and the docking was
run using AutoDock Vina embedded in PyRx program [52]. The docking parameter was defined as
valid, provided that the RMSD values of the complex to be less than 2 Å [27]. Numerous compounds
were published as inhibitors for PEX9 [28,29] and they could be used for the external validation before
the docking parameters were used for in silico screening.
4.4. In Silico Screening
The structures of the natural product compounds (200 ligands) were downloaded from PubChem
and then converted to PDB file using Discovery Studio 3.5. The virtual screening was later done using
the same protocol as that of the control docking. The output was then collected as csv file and the
compounds were tabulated according to the binding affinity. Twenty compounds with the lowest
binding affinity were shortlisted as the in silico hits. The in silico hit compounds then were linked to
the source plants of which they were reported to have been isolated. Based on the availability, eight of
the 20 plants hits were subjected to methanol extraction for in vitro test against MMP9.
4.5. Plant Collections and Extractions
Eight selected plants were collected from Specific Region of Yogyakarta, Sukoharjo District,
and Semarang City located in the Java Island of Indonesia. Plants’ identification was carried out by
referring Flora of Java [53] and further authenticated by Dr. Chusnul Chotimah, Taxonomist of
Herbal Materia Medica, Batu, Malang, Indonesia. The voucher specimens were deposited in
the Laboratory of Herbal Materia Medica, Batu, Malang, Indonesia with specimen numbers as
followed: Hibiscus rosa-sinensis (BMM/0013/36-XI), Ageratum conyzoides (BMM/0013/37-XI), Amaranthus
spinosus (BMM/0013/38-XI), Cordyline fruticosa (BMM/0013/39-XI), Ixora coccinea (BMM/0013/40-XI),
Melaleuca leucadendron (BMM/0013/41-XI), and Turnera diffusa (BMM/0013/42-XI).
4.6. Liquid-Liquid Partitions and Fractionation
Total of 40.0 g of extract was put in separating funnel and 800 mL of distilled water was added.
Around 800 mL of n-hexane was added into the solution and vigorously shaken until dual phase
was formed. The n-hexane phase was collected and then the water phase was re-shaken with ethyl
acetate with the same volume until a clear part appeared in ethyl acetate phase. The obtained
n-hexane and ethyl acetate phases were then evaporated under reduced pressure to collect ethylacetate
partition. The water phase was further partitioned using n-butanol while leaving it as the last
partition. The selected partition based on in vitro assay was subjected for fractionation using column
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chromatography. On one hand, the ethylacetate partition of Ixora (5.0 g) was poured into column
packed up with silica. The mobile phase containing n-hexane: ethyl acetate (3:1) was flowed down
through the column while carrying the compound contained in the partition. On the other hand,
the n-hexane partition of Ageratum (1.0 g) was eluted using n-hexane: ethyl acetate (5:3). The fractions
were collected and then combined, based on the similar TLC profile. The most collected fraction was
then characterized by its chromatography-mass profile using GC-MS (QP2010S Shimadzu).
4.7. In Vitro MMP9 Inhibition Assay
The lyophilized enzyme was reconstituted using 110 µL of glycerol 30% in deionized water.
Then, the enzyme was diluted into 550 µL of buffer and was ready to be used in the assay. The sample
(crude extract/ partitions/ fractions) for the assay was prepared by dissolving it in DMSO to yield
the final concentration of 1 mg/mL in a 96-microwell plate. The final concentration of DMSO in the
well plate was 0.1%. Briefly, the samples were properly mixed with the buffer before adding the
enzyme. The mixture was then incubated at 37 ◦C for 30 min followed by addition of the substrate
(40 µM) and then continued incubating at 37 ◦C for 60 min. The fluorescence was read using Synergy
HTX-3 Multi-mode Reader at 325/393 nm. NNGH inhibitor was prepared using a similar process
except for the final concentration set at 40 µM. Four extracts where the % inhibition reached 50%,
were then subjected to IC50 determination by preparing them in a set of concentrations (0.125 mg/mL;
0.250 mg/mL; 0.500 mg/mL; and 1 mg/mL). Data calculation and the drug-dose dependent curve were
prepared by using GraphPad Prism 5 version 5.01 (www.graphpad.com).
4.8. In Vitro Cytotoxicity Assay
To determine the cytotoxicity of each extract on 4T1, T47D, and Vero cells, the MTT assay was
employed. 4T1 is a triple-negative breast cancer cell line from Mus musculus [54] that contains PEX9
showing 61% homology with PDB 1ITV upon Blast Analysis [55]. T47D is a cell model to characterize
the progesterone-specific effect of a luminal A subtype of breast cancer [56], whereas Vero cell is
a non-tumorigenic cell from the kidney tissue of African green monkey [57]. The assay detects
the reduction of MTT and reflects the normal functioning of mitochondria and hence cytotoxicity.
Cells (1 × 104/well) were seeded in 96-well flat-bottomed plates and incubated with each extract at
various concentrations for 24 h. Doxorubicin was added to the cultures at the following concentrations:
0, 2.5, 5, 10, 20, and 40 µg in a final volume of 100 µL as a positive control using DMSO 0.1%.
Extract solutions were prepared in the following concentrations: 10, 20, 40, 80, 160, 320, 640,
and 1280 µg/mL. Total of 30 µL of MTT solution (5 mg/mL in PBS) was added to each well and
the plate was incubated at 37 ◦C for another 4 h. Then, the medium was discarded and 150 µL
of DMSO was added to dissolve the formazan crystals. The absorbance of each sample was read
at 595 nm using a microplate reader. Results were expressed as a percentage of cell viability with
respect to untreated control cells (as 100%) [58]. The data calculation and the drug-dose dependent
curve were prepared by using GraphPad Prism Version 5.01. Morphological studies were carried
out by visual observation through microscopy (Center Valley, PA, USA). 4T1 Cell were stained
sequentially with 3 mM CellEvent™, Mitotracker RedCMXRos (Invitrogen, Carlsbad, CA, USA),
and Hoechst 33342 (Invitrogen) at a cell concentration of 105 cells/mL in the dark room for 30 min at
37 ◦C. Cell morphology was observed using the Olympus FluoView FV1000 confocal laser scanning
microscope (Center Valley, PA, USA) with a 60X objective and further analyzed using the FV1000
software. Viable cells appeared as leaf-shape and appear white nodes, while dead cells as round and
appear black node.
4.9. Gas Chromatography-Mass Spectroscopy
Total of ± 5 mg of individual fraction 1 (Ixora) and fraction 2 (Ageratum) were dissolved in 1 mL
of chloroform in separated vials. From each vial, 0.5 µL of solution was injected into GC-MS machine
with Rtx 5 MS column (diphenyldiethylpolysiloxane) as the column. The GC is coupled to a mass
Molecules 2020, 25, 4691 14 of 17
spectrometer (Shimadzu QP2010SE, Kyoto, Japan), which has the onus function of recording the mass
spectrum of the chemical compounds as they come out of the GC and after fragmentation processes
by a stream of electrons in the mass spec. Helium gas was used a carrier gas, and the GC oven was
initially held at 100 ◦C for 5 min, and then elevated 5 ◦C per min until reaching 300 ◦C. Peaks in the
chromatograms produced by these analyses were identified by a combination of references to their
mass spectra and the NIST08 mass spectral database.
5. Conclusions
This study provides evidence that in silico study can aid and accelerate the drug discovery process
from natural product. The results also suggest that the aerial part of Ageratum conyzoides has the
potential to be developed as a herbal remedy for breast cancer. However, further investigation is still
needed to confirm its cytotoxicity in a normal human cell and to isolate and elucidate the compounds
that are responsible for the activity at the PEX9 domain of MMP9.
Supplementary Materials: The following are available online, Figure S1: The mass spectra of three peaks
identified from GC chromatogram of Ixora fraction 1., Table S1: The binding affinity of published PEX9 inhibitors
predicted by molecular docking compared to their experimental dissociation constant upon PEX9 inhibition,
Table S2: The yield of Ageratum conyzoides and Ixora coccinea fractions of ethylacetate and n-hexane, respectively.
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